Pharmicell (KO:005690) — Market Cap & Net Worth
Market Cap & Net Worth: Pharmicell (005690)
Pharmicell (KO:005690) has a market capitalization of $470.89 Million (₩694.85 Billion) as of September 18, 2026. Listed on the KO stock exchange, this Korea-based company holds position #12656 globally and #358 in its home market, demonstrating a 7.52% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Pharmicell's stock price ₩11580.00 by its total outstanding shares 60004014 (60.00 Million). Also see Pharmicell assets under control for a full breakdown of the balance sheet.
Pharmicell Market Cap History: 2015 to 2026
Pharmicell's market capitalization history from 2015 to 2026. Data shows growth from $171.40 Million to $470.89 Million (7.82% CAGR). Also see cash efficiency ratio of Pharmicell for how efficiently the company converts equity into cash flow.
Pharmicell Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Pharmicell's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check 005690 live share price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.01x
Pharmicell's market cap is 0.01 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.05x
Pharmicell's market cap is 0.05 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $211.05 Million | $27.84 Billion | -$676.71 Million | 0.01x | N/A |
| 2017 | $231.78 Million | $25.20 Billion | -$39.20 Billion | 0.01x | N/A |
| 2018 | $496.10 Million | $28.35 Billion | -$12.68 Billion | 0.02x | N/A |
| 2019 | $345.24 Million | $32.48 Billion | $4.35 Billion | 0.01x | 0.08x |
| 2020 | $703.48 Million | $37.75 Billion | $5.24 Billion | 0.02x | 0.13x |
| 2021 | $530.66 Million | $51.81 Billion | $9.45 Billion | 0.01x | 0.06x |
| 2022 | $459.50 Million | $60.18 Billion | $8.26 Billion | 0.01x | 0.06x |
| 2023 | $246.83 Million | $56.23 Billion | $3.58 Billion | 0.00x | 0.07x |
| 2024 | $336.70 Million | $64.85 Billion | $6.33 Billion | 0.01x | 0.05x |
Competitor Companies of 005690 by Market Capitalization
Companies near Pharmicell in the global market cap rankings as of September 18, 2026. Review Pharmicell tangible book value ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Pharmicell by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $130.87 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #337 globally with a market cap of $79.84 Billion USD.
- CSL Ltd (AU:CSL): Ranked #455 globally with a market cap of $60.95 Billion USD ( AU$86.14 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #504 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.87 Billion | $516.34 |
| #337 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.84 Billion | $789.45 |
| #455 | CSL Ltd | AU:CSL | $60.95 Billion | AU$177.56 |
| #504 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $158.07 |
Pharmicell Historical Marketcap From 2015 to 2026
Between 2015 and today, Pharmicell's market cap moved from $171.40 Million to $ 470.89 Million, with a yearly change of 7.82%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩470.89 Million | -20.30% |
| 2025 | ₩590.85 Million | +75.48% |
| 2024 | ₩336.70 Million | +36.41% |
| 2023 | ₩246.83 Million | -46.28% |
| 2022 | ₩459.50 Million | -13.41% |
| 2021 | ₩530.66 Million | -24.57% |
| 2020 | ₩703.48 Million | +103.77% |
| 2019 | ₩345.24 Million | -30.41% |
| 2018 | ₩496.10 Million | +114.04% |
| 2017 | ₩231.78 Million | +9.83% |
| 2016 | ₩211.05 Million | +23.13% |
| 2015 | ₩171.40 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of Pharmicell was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $470.89 Million USD |
| MoneyControl | $470.89 Million USD |
| MarketWatch | $470.89 Million USD |
| marketcap.company | $470.89 Million USD |
| Reuters | $470.89 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Pharmicell
Pharmicell Co., Ltd., a biopharmaceutical company, develops and sells stem cell drugs in South Korea and internationally. The company operates in Biopharmaceutical Business and Biochemical Business divisions. It offers Cellgram_AMI that is manufactured using autologous bone marrow-derived mesenchymal stem cell to improve the ejection fraction in patients with acute myocardial infarction reperfuse… Read more